ClinicalTrials.gg
CompletedNCT03918915STARUpdated Jul 30, 2026Results posted

The Safety and Efficacy of SYD-101 in Children With Myopia

A Phase 3 interventional study of SYD-101 0.01% and SYD-101 0.03% in Nearsightedness, Near Sightedness and Near-sightedness, sponsored by Sydnexis, Inc.. Completed at 47 sites in 3 countries. Open to participants aged 3 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Sydnexis, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
852
Allocation
Randomized
Ages
3 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.

Enrollment
Largest of 54
852 · median 144
Started
2019
with 4 others
Phase 3
13 of 54
5 open now
Registered
19th of 54
by date

Among the 54 studies testing atropine in Myopia, this one has the largest enrollment, is one of 5 that started in 2019, is one of 13 in phase 3, and was the 19th registered.

Myopia

1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atropine

Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.

This study: 3 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing atropine in Myopia, or all of them as a file.
02

Study summary

Myopia, or nearsightedness, is the most common eye disorder, often affecting more than 40% of adults in Europe, Asia and the USA. Severe myopia is associated with an increased risk of developing other eye conditions such as glucoma, cataracts and retinal detachment, which may lead to blindness. Early treatment of myopia in children could help slow the condition and minimize the risk of complications later in life. This study investigates the use of SYD-101, an eye solution, in slowing-down the progression of myopia in children.

Read the detailed description

This will be a 3-arm, multicentered, randomized, double-masked, vehicle-controlled study conducted in 2 parts.

Part 1 is the primary treatment period of 3 years, during which participants will receive 1 of 3 masked medications.

Part 2 is the randomized withdrawal period of 1 year, during which participants originally receiving Vehicle will receive SYD-101, and participants originally receiving SYD-101 will receive either Vehicle or SYD-101.

03

Conditions studied

  • Nearsightedness
  • Near Sightedness
  • Near-sightedness

Browse trials for

Keywords

  • Children
  • Myopia
04

Who can participate

Ages eligible
3 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Myopia of 0.5 D (diopters) to 6.00 D (inclusive) in both eyes.
  • Astigmatism ≤1.50 D in both eyes.
  • Anisometropia ≤1.00 D in both eyes.
  • If myopia is ≥0.75 D, participant must be wearing single vision eyeglasses or soft, daily-wear, single-vision contact lenses that meet study investigator's criteria.
  • BCVA (best-corrected visual acuity) Snellen equivalent of 20/32 or better.

Exclusion criteria

Exclusion Criteria:

  • Participants with a history or current evidence of a medical condition predisposing them to degenerative myopia (e.g. Marfan syndrome, Stickler syndrome), or a condition that may affect visual function or development (e.g. diabetes mellitus, chromosome anomaly).
  • Current use of a monoamine oxidase inhibitor.
  • Evidence of any ocular inflammation or infection in either eye, including blepharitis, conjunctivitis, keratitis, and scleritis.
  • Past, present or future plans to use orthokeratology (orthoK), rigid gas-permeable, bifocal, progressive-addition, multi-focal, or other lenses to reduce myopia progression; or the use of atropine, pirenzepine or other anti-muscarinic agent for myopia.
  • History or evidence of ocular surgery or planned future ocular surgery in either eye.

Other protocol-defined inclusion/exclusion criteria could apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
852 participants (actual)

Study arms

  • Experimental
    SYD-101 0.01%

    1 drop in each eye at bedtime. Part 1: participants will be randomized to SYD-101 0.01% Part 2: participants will be re-randomized to SYD-101 0.01% or Vehicle

    Drug: SYD-101 0.01%

  • Experimental
    SYD-101 0.03%

    1 drop in each eye at bedtime. Part 1: participants will be randomized to SYD-101 0.03% Part 2: participants will be re-randomized to SYD-101 0.03% or Vehicle

    Drug: SYD-101 0.03%

  • Placebo comparator
    Vehicle

    1 drop in each eye at bedtime. Part 1: participants will be randomized to Vehicle Part 2: participants will be re-randomized to SYD-101 0.03%

    Drug: Vehicle

Interventions

  • Sterile topical ophthalmic solution

    Also known as: atropine sulfate

  • Sterile topical ophthalmic solution

    Also known as: atropine sulfate

  • DrugVehicle

    Sterile topical ophthalmic solution without active ingredient

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Myopic Progression <-0.75 D (Diopters)

    Proportion of participants with confirmed myopic progression \<-0.75 D (diopters), based on SE (spherical equivalent) as measured by cycloplegic autorefraction

    Time frame: Month 36

Secondary outcomes

  1. Mean Annual Myopic Progression

    Mean annual progression rate of myopia measured in diopters: Spherical Equivalent (SE) as measured by cycloplegic autorefraction.

    Time frame: Month 36

  2. Proportion of Participants With Annual Myopia Progression Rate >=-0.50 D/Year

    Proportion of participants with annual progression rate of myopia no worse than -0.50 D/year

    Time frame: Through Month 36

  3. Proportion of Participants With Annual Myopia Progression Rate >=-0.25 D/Year

    Proportion of participants with annual progression rate of myopia no worse than -0.25D/year

    Time frame: Through Month 36

  4. Proportion of Participants With Increase of Myopia More Than -0.50 D

    Proportion of participants with increase of myopia more than -0.50D

    Time frame: Month 36

  5. Time to Progression of Myopia <-0.75 D (Diopters)

    Time (days) to confirmed myopic progression of worse than -0.75D. Time to Progression (days) 95% CI is calculated for the median.

    Time frame: Up to 36 months (from date of randomization until date myopia progresses < -0.75 D)

  6. Mean Change From Baseline in Axial Length (Subset Only)

    Mean change from baseline in axial length at sites with requisite equipment

    Time frame: Baseline to Month 36

07

Results

Posted Jul 30, 2026

Participant flow

Part 1: Baseline to Month 36
Participant flow — Part 1: Baseline to Month 36
MilestonePart 1: SYD-101 0.01%Part 1: SYD-101 0.03%Part 1: VehiclePart 2: SYD-101 0.01%Part 2: SYD-101 0.03%Part 2: 0.01% to VehiclePart 2: 0.03% to VehiclePart 2: Vehicle to SYD-101 0.03%
Started28428528300000
Received study medication28228328200000
Initiated escape medication151200000
Completed21122322400000
Not completed73625900000
Withdrew: Adverse event05100000
Withdrew: Withdrawal by subject38333300000
Withdrew: Lost to follow-up31222100000
Withdrew: Physician decision, non-compliance, moved20300000
Withdrew: Did not receive study medication22100000
Part 2: Mo 36 to Mo 48 (Withdrawal)
Participant flow — Part 2: Mo 36 to Mo 48 (Withdrawal)
MilestonePart 1: SYD-101 0.01%Part 1: SYD-101 0.03%Part 1: VehiclePart 2: SYD-101 0.01%Part 2: SYD-101 0.03%Part 2: 0.01% to VehiclePart 2: 0.03% to VehiclePart 2: Vehicle to SYD-101 0.03%
Started000102105103105205
Continued escape medication151200000
Initiated escape medication000887109
Completed0009910298101186
Not completed000335419
Withdrew: Adverse event00000002
Withdrew: Withdrawal by subject00021228
Withdrew: Lost to follow-up00012317
Withdrew: Physician decision, protocol deviation, non-compliance, other00000012

Outcome measures

PrimaryMyopic Progression <-0.75 D (Diopters)

Proportion of participants with confirmed myopic progression \<-0.75 D (diopters), based on SE (spherical equivalent) as measured by cycloplegic autorefraction

Time frame:
Month 36
Reported as:
Count of participants · Participants
Myopic Progression <-0.75 D (Diopters)
ParticipantsSYD-101 0.01%SYD-101 0.03%Vehicle
Myopic Progression <-0.75 D (Diopters)111122139
Statistical analysis
  • SYD-101 0.01% vs Vehicle · Cochran-Mantel-Haenszel · p = =0.0226 (Comparison for SYD-101 0.01% vs Vehicle)setting standard error = 1
  • SYD-101 0.03% vs Vehicle · Cochran-Mantel-Haenszel · p = 0.1319setting standard error = 1
SecondaryMean Annual Myopic Progression

Mean annual progression rate of myopia measured in diopters: Spherical Equivalent (SE) as measured by cycloplegic autorefraction.

Time frame:
Month 36
Reported as:
Least squares mean · Diopters/year
Mean Annual Myopic Progression
Diopters/yearSYD-101 0.01%SYD-101 0.03%Vehicle
Mean Annual Myopic Progression-0.30 (-0.34 to -0.27)-0.32 (-0.35 to -0.28)-0.38 (-0.42 to -0.34)
Statistical analysis
  • SYD-101 0.01% vs Vehicle · Mixed Models Analysis · p = 0.0002 · Mean difference (final values): 0.079 · 95% CI 0.038 to 0.120
  • SYD-101 0.03% vs Vehicle · Mixed Models Analysis · p = 0.0018 · Mean difference (final values): 0.067 · 95% CI 0.025 to 0.108
SecondaryProportion of Participants With Annual Myopia Progression Rate >=-0.50 D/Year

Proportion of participants with annual progression rate of myopia no worse than -0.50 D/year

Time frame:
Through Month 36
Reported as:
Count of participants · Participants
Proportion of Participants With Annual Myopia Progression Rate >=-0.50 D/Year
ParticipantsSYD-101 0.01%SYD-101 0.03%Vehicle
Proportion of Participants With Annual Myopia Progression Rate >=-0.50 D/Year240238227
Statistical analysis
  • SYD-101 0.01% vs Vehicle · Mantel Haenszel · p = 0.1706 · Risk difference (rd): 4.48 · 95% CI -2.00 to 10.96
  • SYD-101 0.03% vs Vehicle · Mantel Haenszel · p = 0.2815 · Risk difference (rd): 3.47 · 95% CI -2.83 to 9.77
SecondaryProportion of Participants With Annual Myopia Progression Rate >=-0.25 D/Year

Proportion of participants with annual progression rate of myopia no worse than -0.25D/year

Time frame:
Through Month 36
Reported as:
Count of participants · Participants
Proportion of Participants With Annual Myopia Progression Rate >=-0.25 D/Year
ParticipantsSYD-101 0.01%SYD-101 0.03%Vehicle
Proportion of Participants With Annual Myopia Progression Rate >=-0.25 D/Year163150131
Statistical analysis
  • SYD-101 0.01% vs Vehicle · Mantel Haenszel · p = 0.0102 · Risk difference (rd): 11.01 · 95% CI 2.60 to 19.42
  • SYD-101 0.03% vs Vehicle · Mantel Haenszel · p = 0.1174 · Risk difference (rd): 6.58 · 95% CI -1.71 to 14.87
SecondaryProportion of Participants With Increase of Myopia More Than -0.50 D

Proportion of participants with increase of myopia more than -0.50D

Time frame:
Month 36
Reported as:
Count of participants · Participants
Proportion of Participants With Increase of Myopia More Than -0.50 D
ParticipantsSYD-101 0.01%SYD-101 0.03%Vehicle
Proportion of Participants With Increase of Myopia More Than -0.50 D160171189
Statistical analysis
  • SYD-101 0.01% vs Vehicle · Mantel Haenszel · p = 0.0134 · Risk difference (rd): -10.37 · 95% CI -18.60 to -2.14
  • SYD-101 0.03% vs Vehicle · Mantel Haenszel · p = 0.1054 · Risk difference (rd): -6.56 · 95% CI -14.53 to 1.42
SecondaryTime to Progression of Myopia <-0.75 D (Diopters)

Time (days) to confirmed myopic progression of worse than -0.75D. Time to Progression (days) 95% CI is calculated for the median.

Time frame:
Up to 36 months (from date of randomization until date myopia progresses < -0.75 D)
Reported as:
Median · Days
Time to Progression of Myopia <-0.75 D (Diopters)
DaysSYD-101 0.01%SYD-101 0.03%Vehicle
Time to Progression of Myopia <-0.75 D (Diopters)NA (1101.00 to NA)1112.0 (1099.00 to NA)1104.0 (916.00 to NA)
Statistical analysis
  • SYD-101 0.01% vs Vehicle · Log Rank · p = 0.0071
  • SYD-101 0.03% vs Vehicle · Log Rank · p = 0.0080
SecondaryMean Change From Baseline in Axial Length (Subset Only)

Mean change from baseline in axial length at sites with requisite equipment

Time frame:
Baseline to Month 36
Reported as:
Mean · millimeters
Mean Change From Baseline in Axial Length (Subset Only)
millimetersSYD-101 0.01%SYD-101 0.03%Vehicle
Mean Change From Baseline in Axial Length (Subset Only)0.46 (0.39 to 0.54)0.44 (0.36 to 0.51)0.48 (0.40 to 0.55)
Statistical analysis
  • SYD-101 0.01% vs Vehicle · Mixed Models Analysis · p = 0.7934 · Mean difference (final values): -0.01 · 95% CI -0.11 to 0.08
  • SYD-101 0.03% vs Vehicle · Mixed Models Analysis · p = 0.4452 · Mean difference (final values): -0.04 · 95% CI -0.13 to 0.06

Adverse events

Collected over 48 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: SYD-101 0.01%0/282 (0%)4/282 (1.4%)183/282 (64.9%)
Part 1: SYD-101 0.03%0/283 (0%)10/283 (3.5%)205/283 (72.4%)
Part 1: Vehicle0/282 (0%)8/282 (2.8%)194/282 (68.8%)
Escape Med: 0.03%0/50 (0%)0/50 (0%)17/50 (34%)
Part 2: SYD-101 0.01%0/102 (0%)0/102 (0%)14/102 (13.7%)
Part 2: SYD-101 0.03%0/105 (0%)0/105 (0%)17/105 (16.2%)
Part 2: 0.01% to Vehicle0/103 (0%)0/103 (0%)9/103 (8.7%)
Part 2: 0.03% to Vehicle0/105 (0%)0/105 (0%)14/105 (13.3%)
Part 2: Vehicle to 0.03%0/205 (0%)1/205 (0.5%)60/205 (29.3%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPart 1: SYD-101 0.01%Part 1: SYD-101 0.03%Part 1: VehicleEscape Med: 0.03%Part 2: SYD-101 0.01%Part 2: SYD-101 0.03%Part 2: 0.01% to VehiclePart 2: 0.03% to VehiclePart 2: Vehicle to 0.03%
Suicidal ideationPsychiatric disorders0/2820/2832/2820/500/1020/1050/1030/1050/205
Ulcerative colitisGastrointestinal disorders1/2820/2830/2820/500/1020/1050/1030/1051/205
Pneumonia aspirationInfections and infestations0/2820/2830/2820/500/1020/1050/1030/1051/205
Craniocerebral injuryInjury, poisoning and procedural complications0/2820/2830/2820/500/1020/1050/1030/1051/205
Facial bones fractureInjury, poisoning and procedural complications0/2820/2830/2820/500/1020/1050/1030/1051/205
Pulmonary contusionInjury, poisoning and procedural complications0/2820/2830/2820/500/1020/1050/1030/1051/205
Non fatal intentional drug overdoseInjury, poisoning and procedural complications1/2820/2831/2820/500/1020/1050/1030/1050/205
Commotio cerebriInjury, poisoning and procedural complications1/2820/2830/2820/500/1020/1050/1030/1050/205
PapilledemaEye disorders1/2820/2830/2820/500/1020/1050/1030/1050/205
Transient vision lossEye disorders0/2820/2831/2820/500/1020/1050/1030/1050/205
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPart 1: SYD-101 0.01%Part 1: SYD-101 0.03%Part 1: VehicleEscape Med: 0.03%Part 2: SYD-101 0.01%Part 2: SYD-101 0.03%Part 2: 0.01% to VehiclePart 2: 0.03% to VehiclePart 2: Vehicle to 0.03%
PhotophobiaEye disorders72/28289/28353/2825/503/1025/1051/1030/10519/205
Vision blurredEye disorders30/28254/28326/2822/500/1021/1050/1032/10511/205
HeadacheNervous system disorders35/28246/28351/2823/503/1024/1052/1034/1056/205
COVID 19Infections and infestations30/28233/28346/2823/500/1022/1050/1032/1054/205
Instillation site irritationGeneral disorders24/28227/28329/2821/500/1021/1050/1030/1051/205
MydriasisEye disorders5/28221/2834/2822/500/1020/1050/1030/1058/205
Foreign body sensationEye disorders20/28217/28319/2820/500/1021/1050/1031/1050/205
Eye painEye disorders9/28211/28314/2820/500/1020/1051/1031/1050/205
NasopharyngitisInfections and infestations13/28214/28310/2820/502/1020/1051/1032/1052/205
Eye irritationEye disorders9/2826/28312/2820/503/1022/1050/1030/1052/205

Baseline characteristics

Age, Continuous
Age, Continuous(years)SYD-101 0.01%SYD-101 0.03%VehicleTotal
Mean10.4 ± 2.4410.2 ± 2.4610.4 ± 2.4210.3 ± 2.44
Sex: Female, Male
Sex: Female, Male(Participants)SYD-101 0.01%SYD-101 0.03%VehicleTotal
Female167156149472
Male115127133375
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SYD-101 0.01%SYD-101 0.03%VehicleTotal
Hispanic or Latino747181226
Not Hispanic or Latino208212201621
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SYD-101 0.01%SYD-101 0.03%VehicleTotal
American Indian or Alaska Native2349
Asian465547148
Native Hawaiian or Other Pacific Islander1023
Black or African American35222178
White190192198580
More than one race48416
Unknown or Not Reported43613
Region of Enrollment
Region of Enrollment(participants)SYD-101 0.01%SYD-101 0.03%VehicleTotal
Austria6101026
United States263256258777
Slovakia13171444
Baseline Spherical Equivalent
Baseline Spherical Equivalent(Diopters)SYD-101 0.01%SYD-101 0.03%VehicleTotal
Mean-2.73 ± 1.375-2.65 ± 1.286-2.70 ± 1.267-2.69 ± 1.309
08

Study locations

47 sites
  • Site 143
    Irwindale, California 91706, United States
  • Site 144
    Pasadena, California 91105, United States
  • Site 148
    San Diego, California 92127, United States
  • Site 104
    San Diego, California 92131, United States
  • Site 110
    Santa Barbara, California 93110, United States
  • Site 133
    Sunnyvale, California 94087, United States
  • Site 130
    Colorado Springs, Colorado 80920, United States
  • Site 100
    Fort Collins, Colorado 80528, United States
  • Site 102
    Danbury, Connecticut 06810, United States
  • Site 150
    Waterbury, Connecticut 06708, United States
  • Site 122
    Fort Lauderdale, Florida 33309, United States
  • Site 109
    Jupiter, Florida 33477, United States
  • Site 119
    Sweetwater, Florida 33182, United States
  • Site 120
    Tamarac, Florida 33321, United States
  • Site 124
    Marietta, Georgia 30060, United States
  • Site 116
    Chicago, Illinois 60616, United States
  • Site 106
    Wilmette, Illinois 60091, United States
  • Site 135
    Indianapolis, Indiana 46202, United States
  • Site 131
    Munster, Indiana 46321, United States
  • Site 137
    Pittsburg, Kansas 66762, United States
  • Site 138
    Bangor, Maine 04401, United States
  • Site 123
    Boston, Massachusetts 02111, United States
  • Site 114
    Washington, Missouri 63090, United States
  • Site 132
    Henderson, Nevada 89052, United States
  • Site 139
    Albuquerque, New Mexico 87109, United States
  • Site 127
    Buffalo, New York 14209, United States
  • Site 117
    Chapel Hill, North Carolina 27517, United States
  • Site 121
    Raleigh, North Carolina 27603, United States
  • Site 105
    Fargo, North Dakota 58103, United States
  • Site 111
    Medford, Oregon 97504, United States
  • Site 147
    Tigard, Oregon 97223, United States
  • Sie 136
    Bala-Cynwyd, Pennsylvania 19004-1108, United States
  • Site 128
    Cranberry Township, Pennsylvania 16066, United States
  • Site 108
    Charleston, South Carolina 29425, United States
  • Site 126
    Lakeway, Texas 78734, United States
  • Site 142
    San Antonio, Texas 78215, United States
  • Site 101
    San Antonio, Texas 78240, United States
  • Site 115
    The Woodlands, Texas 77380, United States
  • Site 149
    Ogden, Utah 84403, United States
  • Site 140
    Ogden, Utah 84405, United States
  • Site 113
    Virginia Beach, Virginia 23452, United States
  • Site 204
    Graz, Styria 8036, Austria
  • Site 203
    Linz, Upper Austria 4021, Austria
  • Site 205
    Vienna, 1140, Austria
  • Site 202
    Bratislava, 833 40, Slovakia
  • Site 201
    Trebišov, 075 01, Slovakia
  • Site 200
    Trenčín, 91108, Slovakia
09

References and documents

Publications

  • Johnson P, Widder K, Cheetham J, Kirkeby L. Methods and baseline of a large, multicenter, phase 3 study with low-dose atropine (SYD-101) for the treatment of myopia progression in over 800 children (STAR Study). Invest Ophthalmol Vis Sci. 2025; 66(8), 2825
  • Cheetham JK, Gieschen L, Kirkeby L, Widder K, Johnson P. The natural history of myopia progression in a large diverse pediatric population. Invest Ophthalmol Vis Sci. 2025; 66(8), 2824
  • Korenfeld M, Hurcikova M, Tatsuoka K, Tomcikova D, Cheetham J, Kacerik M; STAR Study Investigators. STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24-Month Results of a Randomized, Double-Masked, Vehicle-Controlled Trial of Atropine Sulfate 0.01% and 0.03. Ophthalmol Ther. 2026 May;15(5):1685-1703. doi: 10.1007/s40123-026-01341-0. Epub 2026 Mar 23. PubMed 41870844 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in May 2024, 60 months.

Results were first posted in Jul 2026, 2 years 2 months after primary completion. A results delay was requested in Feb 2025.

Of 25 phase 3 interventional studies under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 57. This study's 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2019
First posted
Apr 18, 2019
StartActual
Apr 24, 2019
Primary completionActual
May 2, 2024
CompletionActual
May 1, 2025
Results delay requested
Feb 21, 2025
Results first posted
Jul 30, 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03918915
Lead sponsor
Sydnexis, Inc.
Responsible party
Sponsor
First posted
Apr 18, 2019
Start date
Apr 24, 2019
Primary completion
May 2, 2024
Completion
May 1, 2025
Results posted
Jul 30, 2026
Last update
Jul 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atropine

Start the discussion